Literature DB >> 15265929

Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.

Qizhi Yao1, Rongxin Zhang, Lizheng Guo, Min Li, Changyi Chen.   

Abstract

CD4(+) Th cells are believed to be essential for the induction of humoral and cellular immune responses. In this study we tested the effect and possible mechanisms of the major antigenic component in influenza, hemagglutinin (HA), in helping HIV Env to induce immune responses in CD4(+) T cell knockout (CD4 KO) mice. Simian HIV virus-like particles (SHIV VLPs) or phenotypically mixed chimeric influenza HA/SHIV VLPs were used as immunogens to immunize CD4 KO mice either i.p. or intranasally (i.n.). We found that chimeric HA/SHIV VLPs significantly induced a greater IgG Ab response in both i.p. and i.n. immunized mice and a greater IgA Ab response in mucosal washes in i.n. immunized mice compared with SHIV VLPs. Importantly, chimeric HA/SHIV VLPs induced approximately 3-fold higher neutralizing Ab titers against HIV 89.6 than SHIV VLPs in the absence of CD4(+) T cell help. There was also approximately 40% more specific lysis of the HIV Env-expressing target cells in chimeric HA/SHIV VLP-immunized than in SHIV VLP-immunized CD4 KO mouse splenocytes. Moreover, we have found that chimeric HA/SHIV VLPs could efficiently bind and activate dendritic cells and stimulate the activated dendritic cells to secret TNF-alpha and IFN-gamma. Therefore, chimeric HA/SHIV VLPs could efficiently prime and activate APCs, which could, in turn, induce immune responses in a CD4(+) T cell-independent manner. This study suggests a novel adjuvant role of influenza HA as well as a new strategy to develop more effective therapeutic vaccines for AIDS patients with low CD4(+) T cell counts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265929     DOI: 10.4049/jimmunol.173.3.1951

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells.

Authors:  Bangxing Hong; Xiao-Tong Song; Lisa Rollins; Lindsey Berry; Xue F Huang; Si-Yi Chen
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

2.  Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

Authors:  Sheng Zhang; Rafael Cubas; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Immunol       Date:  2009-04-18       Impact factor: 4.407

3.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.

Authors:  Rongxin Zhang; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

4.  Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination.

Authors:  Eunju O; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Yu-Na Lee; Jae-Min Song; Young-Man Kwon; Min-Chul Kim; Daniel R Perez; Sang-Moo Kang
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 5.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

6.  MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination.

Authors:  Sang-Moo Kang; Dae-Goon Yoo; Min-Chul Kim; Jae-Min Song; Min-Kyung Park; Eunju O; Fu-Shi Quan; Shizuo Akira; Richard W Compans
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

7.  Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF.

Authors:  Weifeng Xu; Paul A Santini; Allysia J Matthews; April Chiu; Alessandro Plebani; Bing He; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Authors:  Min Li; Uddalak Bharadwaj; Rongxin Zhang; Sheng Zhang; Hong Mu; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

9.  Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Lei Pan; Zhigao Bu; Richard W Compans; Huizhong Zhang; Chinglai Yang
Journal:  J Biomed Biotechnol       Date:  2010-05-25

Review 10.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.